Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 5

Safety and tolerability of inhalational anticholinergics in COPD

Authors Sharafkhaneh A, Majid H, Gross NJ

Received 13 July 2012

Accepted for publication 30 October 2012

Published 8 March 2013 Volume 2013:5 Pages 49—55


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Amir Sharafkhaneh,1,2 Hashir Majid,3 Nicholas J Gross4

1Baylor College of Medicine, Department of Medicine, Houston, USA; 2Sleep Disorders Center, Michael E DeBakey VA Medical Center, Houston, USA; 3Aga Khan University, Karachi, Pakistan; 4Stritch School of Medicine Illinois, St Francis Hospital, Hartford, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality. With the significant toll of the disease, more resources have been invested in developing new treatment modalities. Among these medications, inhalational anticholinergics are widely used for the management of stable COPD. The newer agents, with longer half-lives and better safety profiles, have emerged and helped to improve management of COPD patients. The available data from randomized clinical trials support use of these agents. Multiple randomized clinical trials show safety and efficacy of the newer long-acting inhaled anticholinergics, including tiotropium and aclidinium. A recent meta-analysis of tiotropium delivered with Respimat® raised some safety concerns. A large trial, comparing different doses and delivery methods of inhaled tiotropium, is ongoing to determine the effect on mortality. As clinical trials may not comprehensively represent the entire COPD population, caution should be exercised when these agents are used in higher-risk populations, like individuals with cardiac arrhythmias or urinary obstruction. In this publication, we review the safety of inhalational anticholinergics.

Keywords: tiotropium, cardiovascular side effects, arrhythmia, stroke, aclidinium

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

What we know about ocular manifestations of Ebola

Moshirfar M, Fenzl CR, Li Z

Clinical Ophthalmology 2014, 8:2355-2357

Published Date: 21 November 2014

Glucose estimation in the salivary secretion of diabetes mellitus patients

Abikshyeet P, Ramesh V, Oza N

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012, 5:149-154

Published Date: 12 July 2012

Is advertising ethical for dentists? An insight into the Indian scenario

Dable RA, Prasanth MA, Singh SB, Nazirkar GS

Drug, Healthcare and Patient Safety 2011, 3:93-98

Published Date: 16 December 2011

Twelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation

Emoto Y, Emoto H, Oishi E, Hikita S, Wakakura M

Drug, Healthcare and Patient Safety 2011, 3:9-14

Published Date: 3 June 2011

Moving towards implementation of a clinical ethics consultation program in Egyptian liver transplant units

A H El-Elemi, G H El-Gazzaz

Transplant Research and Risk Management 2010, 2:23-27

Published Date: 16 March 2010

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Louise Profit, Paul Chrisp, Carole Nadin

Core Evidence 2008, 3:0-0

Published Date: 31 December 2008

Ciclesonide in persistent asthma: the evidence of its therapeutic value

Charlotte A. Kenreigh, Linda Timm Wagner, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006